CSF3 and Miyoshi myopathy: Thus it appears, based on these data, that a single injection of motixafortide added to G-CSF substantially improves on currently approved mobilization regimens in terms of the rapidity, robustness and reliability of HSPC mobilization for ASCT in patients newly diagnosed with MM following modern induction therapy in the current era.